The Catholic University of Korea Industry-Academic Cooperation Foundation

Catholic University Industry Academic Cooperation Foundation

Hanlim Pharmaceutical Co., Ltd.

Bifido Co., Ltd.

Joo-Yeon Jhun

Mi-La Cho

Seon-Yeong Lee

Sung-Hwan Park

Chul-Woo Yang

Jong-Young Choi

Hyeon-Beom Seo

Jae-yoon Ryu

Ji-Won Kim

Min-Jung Park

Jin-Ha Park

Dong-Yun Shin

Geun-Hyeog Lee

Geun Eog Ji

Hee-yeon Kim

Jun-Geol Ryu

Seung-Ki Kwok

Hye-Jwa Oh

Kyoung-Woon Kim

Jun-Ki Min

Yun-Ju Woo

Eun-Young Kwak

Bin Kwon

Ji-Hyeon Ju

Se-Young Kim

Jennifer Lee

Jae-Kyeong Byun

Ye-Been Yim

Byung-Ha Chung

Yunju Jeong

Se-Wan Park

Hui Fang

Keun-Hyung Cho

The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

Provided is a composition containingfor alleviating, preventing or treating rheumatoid arthritis. TheATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Composition containingfor alleviating, preventing or treating rheumatoid arthritis

The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.

Kit for monitoring immune status after transplant and method for monitoring immune status using same

The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

Pharmaceutical composition for preventing or treating rheumatoid arthritis, containing rebamipide

Growing community of inventors

Seoul, South Korea

Joo-Yeon Jhun